Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial

BACKGROUND: While the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clini...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate
Autors principals: Chen, Haitao, Na, Rong, Packiam, Vignesh T., Conran, Carly A., Jiang, Deke, Tao, Sha, Yu, Hongjie, Lin, Xiaoling, Meng, Wei, Zheng, S. Lilly, Brendler, Charles B., Helfand, Brian T., Xu, Jianfeng
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6949015/
https://ncbi.nlm.nih.gov/pubmed/28670847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23369
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars